Newly identified properties of known pharmaceuticals and myxobacterial small molecules revealed by screening for autophagy modulators
The FEBS Journal · 2025
DOI: 10.1111/febs.70243 ↗At a glance
Journal article in The FEBS Journal, 2025. Written by Janine Fichtner and 13 co-authors. Institution: Systems-Oriented Immunology and Inflammation Research Group, Helmholtz Centre for Infection Research, Braunschweig, Germany. Major MEDLINE topics: Autophagy, Myxococcales. 67 references. The full text is freely available (open access, CC BY 4.0). Funded by: Helmholtz-Gemeinschaft, Faculty of Medicine and Institute of Biomedicine, University of Turku, Deutsche Forschungsgemeinschaft.
Abstract (original language)
Autophagy is a cellular degradation and recycling process important for maintaining cellular health and function. It is constitutively active at a low level in eukaryotic cells and can be induced by conditions of cellular stress, such as nutrient starvation. Moreover, autophagy plays an important role in diverse processes such as immunobiology, pathogen infection, ageing, and neurodegenerative and other diseases. Using a high‐content fluorescence assay for microtubule‐associated protein 1 light chain 3 beta (LC3B), a major player in the autophagic pathway, we screened a library of commercial drugs and natural products for activators and inhibitors of LC3B‐positive vesicle accumulation. Positive hits for known autophagy modulators included anisomycin, amphotericin B, carbonyl cyanide m‐chlorophenylhydrazone (CCCP) and cytochalasin D. Importantly, we identified several new autophagy modulators, such as aciclovir and myxobacterial vioprolides. Anisomycin, aciclovir and vioprolides promoted intracellular growth of Staphylococcus aureus , a bacterium that is known to be a target of autophagy. In contrast, anisomycin strongly inhibited influenza A virus and SARS‐CoV‐2 replication. Subsequently, we investigated the influence of these autophagy modulators in a cellular disease model of neuronal vacuolation and spinocerebellar degeneration (NVSD), which is associated with cysteine protease ATG4D mutations. We provide evidence that anisomycin and famciclovir, an aciclovir analogue, can normalise the elevated amount of LC3‐positive vesicles in mutant fibroblasts, highlighting their potential for the treatment of NVSD. Thus, the screening method enabled the identification of autophagy‐modulating compounds with therapeutic potential.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Systems-Oriented Immunology and Inflammation Research Group, Helmholtz Centre for Infection Research, Braunschweig, Germany.
- Institute of Biomedicine, University of Turku, Finland.
- Department of Molecular Immunology, Ruhr University Bochum, Germany.
- Department of Microbial Drugs, Helmholtz Centre for Infection Research, Braunschweig, Germany.
- German Centre for Infection Research (DZIF), Partner site Hannover-Braunschweig, Germany.
- Department of Pharmacy, Helmholtz Institute for Pharmaceutical Research Saarland (HIPS), Helmholtz Centre for Infection Research (HZI) and Saarland University, Saarbrücken, Germany.
ORCID profiles: Janine Fichtner, Yan Yan Beer, H G Mauricio Ramm, Sabrina Mühlen, Frank Surup, Jennifer Herrmann, Toni Luise Meister, Stephanie Pfaender, Ursula Bilitewski, Mark Brönstrup, Eeva-Liisa Eskelinen, Ingo Schmitz
Funding
- Helmholtz-Gemeinschaft
- Faculty of Medicine and Institute of Biomedicine, University of Turku
- Deutsche Forschungsgemeinschaft
- German Center for Infection Research
- Helmholtz Association
- Deutsches Zentrum für Infektionsforschung
Cite
APA
Fichtner, J., Beer, Y. Y., Ramm, H. G. M., Mühlen, S., Surup, F., Herrmann, J., Meister, T. L., Pfaender, S., Bilitewski, U., Brönstrup, M., Müller, R., Wirth, M., Eskelinen, E. L., & Schmitz, I. (2025). Newly identified properties of known pharmaceuticals and myxobacterial small molecules revealed by screening for autophagy modulators. The FEBS Journal. https://doi.org/10.1111/febs.70243
Vancouver
Fichtner J, Beer YY, Ramm HGM, Mühlen S, Surup F, Herrmann J, et al. Newly identified properties of known pharmaceuticals and myxobacterial small molecules revealed by screening for autophagy modulators. The FEBS Journal. 2025. doi:10.1111/febs.70243
BibTeX
@article{Fichtner2025,
author = {Fichtner, Janine and Beer, Yan Yan and Ramm, H G Mauricio and Mühlen, Sabrina and Surup, Frank and Herrmann, Jennifer and Meister, Toni Luise and Pfaender, Stephanie and Bilitewski, Ursula and Brönstrup, Mark and Müller, Rolf and Wirth, Manfred and Eskelinen, Eeva-Liisa and Schmitz, Ingo},
title = {Newly identified properties of known pharmaceuticals and myxobacterial small molecules revealed by screening for autophagy modulators},
journal = {The FEBS Journal},
year = {2025},
doi = {10.1111/febs.70243}
}
EUVIMED